MicroPort NeuroTech™ Receives NMPA Marketing Approval for its Diveer^® Intracranial Balloon Catheter

Shanghai, China, 27 January 2022 - MicroPort NeuroTech Limited (MicroPort NeuroTech™) has received marketing approval from China’s National Medical Products Administration (NMPA) for its independently-developed Diveer® Intracranial Balloon Catheter (Diveer®).

The approved Diveer® Intracranial Balloon Catheter is a specialized rapid-exchange intracranial balloon catheter, indicated for the interventional therapy of symptomatic Intracranial atherosclerotic stenosis (ICAS) in the non-acute phase. During surgery, the balloon catheter is delivered to the vascular lesion through a guidewire, and then inflated to expand the narrowed lumen, thereby improving the perfusion in the intracranial artery. Diveer®’s ultra-soft tip reduces the risk of vascular injury, and its low resistance enables exceptional navigability in tortuous vessels and complex lesions.

ICAS is one of the major causes of ischemic stroke, which is prevalent in Asian populations. ICAS is easily overlooked due to few early symptoms before the onset, and therefore mortality and disability rates of ischemic stroke caused by ICAS remain high in China. Available treatments include medicine, surgical operations, and endovascular intervention, a procedure which alters the vessel morphology through physical intervention, resulting in a better therapeutic effect, less trauma, and faster recovery after the procedure compared to other treatment methods.

The market approval of the Diveer® Intracranial Balloon Catheter further enhances MicroPort NeuroTech™’s product portfolio for the treatment of ICAS and provides more options for clinical practices. MicroPort NueroTech™ will continue to promote product innovation and improve its universal, affordable and comprehensive medical solutions for hemorrhagic stroke, intracranial atherosclerotic stenosis, and acute ischemic stroke.